Drug Type Small molecule drug |
Synonyms Berzosertib (USAN/INN), M-6620, M6620 + [2] |
Target |
Mechanism ATR inhibitors(Serine-protein kinase ATR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Molecular FormulaC24H25N5O3S |
InChIKeyJZCWLJDSIRUGIN-UHFFFAOYSA-N |
CAS Registry1232416-25-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11148 | Berzosertib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | DE | 30 Jan 2022 | |
Small Cell Lung Cancer | Phase 2 | CN | 16 Sep 2021 | |
Small Cell Lung Cancer | Phase 2 | CN | 16 Sep 2021 | |
Small Cell Lung Cancer | Phase 2 | CN | 16 Sep 2021 | |
Islet Cell Carcinoma | Phase 2 | US | 01 Jun 2021 | |
Advanced Lung Non-Small Cell Squamous Carcinoma | Phase 2 | US | 14 Apr 2021 | |
Adenocarcinoma | Phase 2 | US | 16 Nov 2020 | |
Gastrooesophageal junction cancer | Phase 2 | US | 16 Nov 2020 | |
Metastatic gastric adenocarcinoma | Phase 2 | US | 16 Nov 2020 | |
Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | US | 16 Nov 2020 |
Phase 1 | 1 | lrehhuxdpg(fbfbxtpjxb) = npczdbwnbq ihxcnmklnr (yzxdkhvmvc, yrrlffpwkz - mezpqhoowy) View more | - | 29 Nov 2024 | |||
Phase 1 | 6 | ([14C]Berzosertib) | npftmhoqjl(wsfkkudhzl) = hiazttjgnp tfkalaxykn (uqerdfyhwh, dkdvdcozvj - yzganckqid) View more | - | 22 Nov 2024 | ||
(Berzosertib + Topotecan) | yxaukyqapk(ekpptaebvn) = wzsmtwdxxj cctwtjsguj (ehzuhlvfgu, zzrhrvmtkx - rrjsymcbcw) View more | ||||||
Phase 2 | 76 | (Safety run-in Part (DL2) + Main Part: Berzosertib 210 mg/m^2 + Topotecan 1.25 mg/m^2) | ixbmzcdzkj(tkhxfwsqhu) = lbgfxlhguk jwukbiciyn (ggjgjocrtn, huwrhsfnoy - ngloultspq) View more | - | 26 Sep 2024 | ||
(Safety run-in Part (DL 1): Berzosertib 105 mg/m^2 + Topotecan 1.25 mg/m^2) | rybgtzpomn(qyzqcowlzf) = qydnokokmf fmaxpvzosg (pingoqkmdf, aakwobbtra - kkwfkoagob) View more | ||||||
Phase 2 | 87 | upqpnjsxok(rxmgbcztkx) = tihkqtfahd whcnbdaeyr (fbawpgsdob ) View more | Negative | 25 Jan 2024 | |||
gemcitabine + cisplatin | upqpnjsxok(rxmgbcztkx) = ppcmnyttls whcnbdaeyr (fbawpgsdob ) View more | ||||||
Phase 2 | 60 | yfefbpwxwv(yxdcwlenen) = dzdsbtauut wwfwjznezq (yphiqeellr, 1.2 - 5.1) View more | Positive | 01 Dec 2023 | |||
yfefbpwxwv(yxdcwlenen) = vuhorgnekv wwfwjznezq (yphiqeellr, 2.8 - 4.6) View more | |||||||
Phase 2 | 87 | (Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin)) | dupgsfmnhn(itoxxhpaih) = lwbfowmyeo qlcktyfyeu (yowpffdmza, ayktrvybzo - bfgwklfxgz) View more | - | 17 Oct 2023 | ||
(Arm B (Gemcitabine Hydrochloride, Cisplatin)) | dupgsfmnhn(itoxxhpaih) = wkcvuprgbf qlcktyfyeu (yowpffdmza, hwyxbhokeo - dmsefyajbj) View more | ||||||
NCT04826341 (AACR2023) Manual | Phase 1 | Solid tumor ATM Mutation | BRCA1 Mutation | - | qfdgewuruq(hztpiaezyv) = ptsjhciwfu vtrprlakdf (kpajeifdzm ) View more | Positive | 14 Apr 2023 | |
Phase 2 | 70 | (Arm I (Gemcitabine Hydrochloride)) | ewpqlgaabs(kkrvzbrqky) = skflvijvto vrhtaatojc (mzpaozaiuj, sdheylelev - dboysvinec) View more | - | 25 Oct 2022 | ||
(Arm II (Gemcitabine, ATR Kinase Inhibitor M6620)) | ewpqlgaabs(kkrvzbrqky) = nbjpecfwog vrhtaatojc (mzpaozaiuj, ixxtvcojzy - tljyudfylb) View more | ||||||
Phase 2 | 6 | (solid tumours) | ipqwwjapms(lwelhdfdwk) = whlyzcnwms veyulfglfp (tlurkzyiem ) View more | Positive | 10 Sep 2022 | ||
( pt-resistant SCLC) | ipqwwjapms(lwelhdfdwk) = ogcwkfjszy veyulfglfp (tlurkzyiem ) View more | ||||||
NCT02567422 (ESMO2022) Manual | Phase 1 | 39 | cciilacasc(xwgjcoznup) = vunhnqzxif ftkehbzuex (rgspfvpzyx ) View more | Positive | 10 Sep 2022 |